0.80
0.80 (0%)
As of Feb 14, 2025
Indaptus Therapeutics, Inc. [INDP]
Source:
Company Overview
Indaptus Therapeutics, Inc is a clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.We have evolved from more than a century of immunotherapy advances.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (646) 427-2727 |
| Industry | manufacturing |
| CEO | Jeffrey A. Meckler |
| Website | www.indaptusrx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-15.4 |
| Net Income | $-15 |
| Net Cash | $-7.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -135% |
| Profit as % of Stockholder Equity | -380.8% |
Management Effectiveness
| Return on Equity | -380.8% |
| Return on Assets | -204.7% |
| Turnover Ratio | |
| EBITA | $-15.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $7.3 |
| Total Liabilities | $3.4 |
| Operating Cash Flow | $-12.3 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $4.7 |
